National Institute of Allergy and Infectious Diseases; Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Design and Screening of Protease-Resistant Synthetic Peptides With the Anti-Tumor and Immunodulating Activity

Resumen

The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health is seeking capability statements from parties interested in entering into a Cooperative Research and Development Agreement (CRADA) on a project to design and screen protease-resistant synthetic peptides with anti-tumor and immunomodulating activity. This project is with the Laboratory of Immunology (LI). The proposed project is based on NIAID's identification and on biochemical characterization of functionally important individual proteins/enzymes or surface receptors which have been implicated in the lymphocyte activation/differentiation or as having anti-tumor activity. These proteins include: (1) The novel set of ectoproteins (enyzmes), which are located on the cell surface and utilize extracellular ATP [ectoprotein phosphatases, ectoprotein kinases and ectoATPases as well as the purinergic receptors (ATP-receptor)]; and (2) Intracellular catalytic subunit of the cAMP-dependent protein kinase. The goal is to develop specific reagents (protease-resistant synthetic peptides and monoclonal antibody) which will either mimic the cytotoxic properties of ATP or will inhibit extracellu